294 related articles for article (PubMed ID: 31034883)
1. Insulin-Like Growth Factor and SLC12A7 Dysregulation: A Novel Signaling Hallmark of Non-Functional Adrenocortical Carcinoma.
Brown TC; Nicolson NG; Stenman A; Juhlin CC; Gibson CE; Callender GG; Korah R; Carling T
J Am Coll Surg; 2019 Sep; 229(3):305-315. PubMed ID: 31034883
[TBL] [Abstract][Full Text] [Related]
2. DNA copy amplification and overexpression of SLC12A7 in adrenocortical carcinoma.
Brown TC; Juhlin CC; Healy JM; Stenman A; Rubinstein JC; Korah R; Carling T
Surgery; 2016 Jan; 159(1):250-7. PubMed ID: 26454676
[TBL] [Abstract][Full Text] [Related]
3. SLC12A7 alters adrenocortical carcinoma cell adhesion properties to promote an aggressive invasive behavior.
Brown TC; Murtha TD; Rubinstein JC; Korah R; Carling T
Cell Commun Signal; 2018 Jun; 16(1):27. PubMed ID: 29884238
[TBL] [Abstract][Full Text] [Related]
4. IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer.
De Martino MC; van Koetsveld PM; Feelders RA; de Herder WW; Dogan F; Janssen JAMJL; Hofste Op Bruinink D; Pivonello C; Waaijers AM; Colao A; de Krijger RR; Pivonello R; Hofland LJ
Endocrine; 2019 Jun; 64(3):673-684. PubMed ID: 30838516
[TBL] [Abstract][Full Text] [Related]
5. BCL9 Upregulation in Adrenocortical Carcinoma: A Novel Wnt/β-Catenin Activating Event Driving Adrenocortical Malignancy.
Brown TC; Nicolson NG; Korah R; Carling T
J Am Coll Surg; 2018 Jun; 226(6):988-995. PubMed ID: 29428231
[TBL] [Abstract][Full Text] [Related]
6. The role of insulin-like growth factor system in the adrenocortical tumors.
Altieri B; Colao A; Faggiano A
Minerva Endocrinol; 2019 Mar; 44(1):43-57. PubMed ID: 29963827
[TBL] [Abstract][Full Text] [Related]
7. IGF2 and IGF1R in pediatric adrenocortical tumors: roles in metastasis and steroidogenesis.
Peixoto Lira RC; Fedatto PF; Marco Antonio DS; Leal LF; Martinelli CE; de Castro M; Tucci S; Neder L; Ramalho L; Seidinger AL; Cardinalli I; Mastellaro MJ; Yunes JA; Brandalise SR; Tone LG; Rauber Antonini SR; Scrideli CA
Endocr Relat Cancer; 2016 Jun; 23(6):481-93. PubMed ID: 27185872
[TBL] [Abstract][Full Text] [Related]
8. Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma.
Xu L; Qi Y; Xu Y; Lian J; Wang X; Ning G; Wang W; Zhu Y
Oncotarget; 2016 Jun; 7(24):36235-36246. PubMed ID: 27105537
[TBL] [Abstract][Full Text] [Related]
9. The cytoskeleton actin binding protein filamin A impairs both IGF2 mitogenic effects and the efficacy of IGF1R inhibitors in adrenocortical cancer cells.
Catalano R; Giardino E; Treppiedi D; Mangili F; Morelli V; Elli FM; Serban AL; Luconi M; Mannelli M; Spada A; Arosio M; Mantovani G; Peverelli E
Cancer Lett; 2021 Jan; 497():77-88. PubMed ID: 33075426
[TBL] [Abstract][Full Text] [Related]
10. Livin/BIRC7 expression as malignancy marker in adrenocortical tumors.
Altieri B; Sbiera S; Della Casa S; Weigand I; Wild V; Steinhauer S; Fadda G; Kocot A; Bekteshi M; Mambretti EM; Rosenwald A; Pontecorvi A; Fassnacht M; Ronchi CL
Oncotarget; 2017 Feb; 8(6):9323-9338. PubMed ID: 28030838
[TBL] [Abstract][Full Text] [Related]
11. IGF1-R inhibition and liposomal doxorubicin: Progress in preclinical evaluation for the treatment of adrenocortical carcinoma.
Beuschlein F; Jakoby J; Mentz S; Zambetti G; Jung S; Reincke M; Süss R; Hantel C
Mol Cell Endocrinol; 2016 Jun; 428():82-8. PubMed ID: 26994514
[TBL] [Abstract][Full Text] [Related]
12. Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line.
Logié A; Boulle N; Gaston V; Perin L; Boudou P; Le Bouc Y; Gicquel C
J Mol Endocrinol; 1999 Aug; 23(1):23-32. PubMed ID: 10425444
[TBL] [Abstract][Full Text] [Related]
13. Analysis of IGF and IGFBP as prognostic serum biomarkers for adrenocortical carcinoma.
Patel D; Ellis R; Howard B; Boufraqech M; Gara SK; Zhang L; Quezado MM; Nilubol N; Kebebew E
Ann Surg Oncol; 2014 Oct; 21(11):3541-7. PubMed ID: 24833102
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas.
Ilvesmäki V; Kahri AI; Miettinen PJ; Voutilainen R
J Clin Endocrinol Metab; 1993 Sep; 77(3):852-8. PubMed ID: 8370710
[TBL] [Abstract][Full Text] [Related]
15. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.
Barlaskar FM; Spalding AC; Heaton JH; Kuick R; Kim AC; Thomas DG; Giordano TJ; Ben-Josef E; Hammer GD
J Clin Endocrinol Metab; 2009 Jan; 94(1):204-12. PubMed ID: 18854392
[TBL] [Abstract][Full Text] [Related]
16. IGF2 role in adrenocortical carcinoma biology.
Pereira SS; Monteiro MP; Costa MM; Moreira Â; Alves MG; Oliveira PF; Jarak I; Pignatelli D
Endocrine; 2019 Nov; 66(2):326-337. PubMed ID: 31378849
[TBL] [Abstract][Full Text] [Related]
17. Amplification of the insulin-like growth factor 1 receptor gene is a rare event in adrenocortical adenocarcinomas: searching for potential mechanisms of overexpression.
Ribeiro TC; Jorge AA; Almeida MQ; Mariani BM; Nishi MY; Mendonca BB; Fragoso MC; Latronico AC
Biomed Res Int; 2014; 2014():936031. PubMed ID: 25110710
[TBL] [Abstract][Full Text] [Related]
18. Targeting estrogen receptor-α reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment.
Sirianni R; Zolea F; Chimento A; Ruggiero C; Cerquetti L; Fallo F; Pilon C; Arnaldi G; Carpinelli G; Stigliano A; Pezzi V
J Clin Endocrinol Metab; 2012 Dec; 97(12):E2238-50. PubMed ID: 23074235
[TBL] [Abstract][Full Text] [Related]
19. An integrin binding-defective mutant of insulin-like growth factor-1 (R36E/R37E IGF1) acts as a dominant-negative antagonist of the IGF1 receptor (IGF1R) and suppresses tumorigenesis but still binds to IGF1R.
Fujita M; Ieguchi K; Cedano-Prieto DM; Fong A; Wilkerson C; Chen JQ; Wu M; Lo SH; Cheung AT; Wilson MD; Cardiff RD; Borowsky AD; Takada YK; Takada Y
J Biol Chem; 2013 Jul; 288(27):19593-603. PubMed ID: 23696648
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor system on adrenocortical tumorigenesis.
Ribeiro TC; Latronico AC
Mol Cell Endocrinol; 2012 Mar; 351(1):96-100. PubMed ID: 22019903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
